文献速递淋巴瘤

PI3Kδ抑制重塑滤泡性淋巴瘤免疫微环境交互并增强venetoclax活性

PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.
PubMed 文献 · Blood Adv · 2020-01-01

该研究通过42例滤泡性淋巴瘤患者活检组织与滤泡树突状细胞体外共培养,发现PI3Kδ抑制剂idelalisib可干扰血管生成、细胞外基质形成及跨内皮迁移相关基因,并普遍干扰CD40/CD40L通路、下调CCL22,重塑免疫微环境;同时恢复肿瘤对BCL-2的依赖,增强venetoclax的细胞毒活性。

要点

  • idelalisib对部分FL样本的血管生成和播散相关基因有患者依赖性影响,可定义18基因敏感性指纹。
  • idelalisib普遍干扰CD40/CD40L通路和B-T细胞突触相关蛋白,削弱FL细胞与TFH的交互。
  • idelalisib下调CCL22减少TFH和Treg募集,并恢复FL对BCL-2的依赖,增强venetoclax活性。

核心结论

  • idelalisib对血管生成和淋巴瘤播散的作用具有患者依赖性,但普遍重塑FL免疫微环境并恢复对BCL-2的依赖,为联合venetoclax提供机制依据。

研究设计与样本

  • 研究采用42例FL患者活检组织与滤泡树突状细胞体外共培养模型模拟生发中心,并结合BH3 profiling分析。

主要发现

  • idelalisib干扰部分FL样本中FDC诱导的血管生成、细胞外基质形成和跨内皮迁移相关基因,定义18基因敏感性指纹。
  • idelalisib普遍干扰CD40/CD40L通路和增殖,下调B-T细胞突触关键蛋白,导致FL细胞与TFH交互低效。
  • idelalisib下调CCL22,减少TFH和免疫抑制性Treg向FL微环境募集,形成支持性及耐受性较低的免疫微环境。
  • FL-FDC和FL-巨噬细胞共培养分别增加肿瘤对BCL-XL和MCL-1或BFL-1的依赖,限制venetoclax的细胞毒活性。
  • idelalisib恢复FL对BCL-2的依赖和venetoclax活性。

临床怎么用

  • idelalisib可重塑FL免疫微环境并恢复BCL-2依赖,支持在临床试验中探索PI3Kδ抑制剂联合venetoclax。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite idelalisib approval in relapsed follicular lymphoma (FL), a complete characterization of the immunomodulatory consequences of phosphatidylinositol 3-kinase δ (PI3Kδ) inhibition, biomarkers of response, and potential combinatorial therapies in FL remain to be established. Using ex vivo cocultures of FL patient biopsies and follicular dendritic cells (FDCs) to mimic the germinal center (n = 42), we uncovered that PI3Kδ inhibition interferes with FDC-induced genes related to angiogenesis, extracellular matrix formation, and transendothelial migration in a subset of FL samples, defining an 18-gene signature fingerprint of idelalisib sensitivity. A common hallmark of idelalisib found in all FL cases was its interference with the CD40/CD40L pathway and induced proliferation, together with the downregulation of proteins crucial for B-T-cell synapses, leading to an inefficient cross talk between FL cells and the supportive T-follicular helper cells (TFH). Moreover, idelalisib downmodulates the chemokine CCL22, hampering the recruitment of TFH and immunosupressive T-regulatory cells to the FL niche, leading to a less supportive and tolerogenic immune microenvironment. Finally, using BH3 profiling, we uncovered that FL-FDC and FL-macrophage cocultures augment tumor addiction to BCL-XL and MCL-1 or BFL-1, respectively, limiting the cytotoxic activity of the BCL-2 inhibitor venetoclax. Idelalisib restored FL dependence on BCL-2 and venetoclax activity. In summary, idelalisib exhibits a patient-dependent activity toward angiogenesis and lymphoma dissemination. In all FL cases, idelalisib exerts a general reshaping of the FL immune microenvironment and restores dependence on BCL-2, predisposing FL to cell death, providing a mechanistic rationale for investigating the combination of PI3Kδ inhibitors and venetoclax in clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Serrat N, Guerrero-Hernández M, Matas-Céspedes A, et al. PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Adv. 2020. PMID: 32898249. doi:10.1182/bloodadvances.2020001584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。